White label ELPA - ClinicalTrials.eu

Study of Eltrekibart for Adults with Moderate to Severe Hidradenitis Suppurativa

Not recruiting

2 1
Investigated diseases:
- Hidradenitis
Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Not recruiting

3 1

+7
Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Not recruiting

3 1 1
Investigated diseases:
- Pulmonary embolism
+2
Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors

Not recruiting

2 1 1 1
Investigated diseases:
Study on Ianalumab for Patients with Systemic Lupus Erythematosus

Not recruiting

3 1 1
Investigated diseases:
- Systemic lupus erythematosus
Study on the Effects of Selpercatinib in Children with Advanced RET-Altered Solid Tumors or Primary Central Nervous System Tumors

Not recruiting

1 1 1 1
Investigated diseases:
Study of trametinib and hydroxychloroquine in patients with metastatic pancreatic cancer that has not responded to previous treatment

Not recruiting

2 1 1 1
Investigated diseases:
- Pancreatic carcinoma metastatic
Study on Sotorasib for Patients with Unresectable Stage III Non-Small Cell Lung Cancer with KRAS Mutation

Not recruiting

2 1 1 1
Investigated diseases:
- Non-small cell lung cancer stage III
Study of ALX148 and Azacitidine for Untreated Higher Risk Myelodysplastic Syndrome Patients

Not recruiting

1 1 1 1
Investigated diseases:
- Myelodysplastic syndrome
Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Not recruiting

3 1 1 1
Investigated diseases:
- Clear cell papillary renal cell carcinoma
+2

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies